Non-CF-Bronchiektasen mit Fokus auf die allergische bronchopulmonale Aspergillose

Lernziel

Der CME-Artikel soll einen Überblick zur Epidemiologie, klinischen Relevanz, erforderlichen Differenzialdiagnostik und zum therapeutischen Management der nicht mit zystischer Fibrose (CF) assoziierten (Non-CF) Bronchiektasen vermitteln. Besondere Beachtung finden aktuell Entwicklungen, die das sekretolytische und antimikrobielle Management betreffen sowie die allergische bronchopulmonale Aspergillose (ABPA) als eine der vergleichweise häufig anzutreffenden Ursachen einer Bronchiektasie.

• Literatur

• 1 Laennac RTH. De l’Auscultation Mediate ou Traite du Diagnostic des Maladies des Poumons et du Coeur. Paris: Brosson and Chaudé; 1819
• 2 Twiss J, Metcalfe R, Edwards E et al. New Zealand national incidence of bronchiectasis "too high" for a developed country. Arch Dis Child 2005; 90: 737-740
• 3 Seitz A, Kenneth O, Steiner C et al. Trends and burden of bronchiectasis- associated hospitalisations: USA, 1993-2006. Chest 2010; 138: 944-949
• 4 Bilton D, Jones AL. Bronchiectasis: epidemiology and causes. Eur Respir Mon 2011; 52: 1-10
• 5 Shoemark A, Ozerovitch L, Wilson R. Aetiology in adult patients with bronchiectasis. Respir Med 2007; 101: 1163-1170
• 6 Pasteur MC, Helliwell SM, Houghton SJ et al. An investigation into causative factors in patients with bronchiectasis. Am J Respir Crit Care Med 2000; 162: 1277-1284
• 7 Goeminne P, Dupont L. Non-cystic fibrosis bronchiectasis: diagnosis and management in 21st century. Postgrad Med J 2010; 86: 493-501
• 8 Li AM, Sonnappa S, Lex C et al. Non-CF bronchiectasis: does knowing the aetiology lead to changes in management?. Eur Respir J 2005; 26: 8-14
• 9 Stead A, Douglas JG, Broadfoot CJ et al. Humoral immunity and bronchiectasis. Clin Exp Immunol 2002; 130: 325-330
• 10 Notarangelo LD, Plebani A, Mazzolari E et al. Genetic causes of bronchiectasis: primary immune deficiencies and the lung. Respiration 2007; 74: 264-275 Review
• 11 Pasteur M, Bilton D, Hill A et al. British Thoracic Society Guideline for non-CF bronchiectasis. Thorax 2010; 65: 1-58
• 12 Brown JS, Baxendale H, Floto RA. Immunodefiencies associated with bronchiectasis. Eur Respir Mon 2011; 52: 178-191
• 13 Donaldson SH, Bennett WD, Zeman KL et al. Mucus clearance and lung function in cystic fibrosis with hypertonic saline. N Engl J Med 2006; 354: 241-250
• 14 Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients with stable bronchiectasis. Resp Med 2005; 99: 27-31
• 15 Daviskas E, Anderson SD, Gomes K et al. Inhaled mannitol for the treatment of mucociliary dysfunction in patients with bronchiectasis: effect on lung function, health status and sputum. Respirology 2005; 10: 46-56
• 16 Burness CB, Keating GM. Mannitol dry powder for inhalation: in patients with cystic fibrosis. Drugs 2012; 72: 1411-1421
• 17 O'Donnell AE, Barker AF, Ilowite JS. rhDNase Study Group et al. Treatment of idiopathic bronchiectasis with aerosolized recombinant human DNase. Chest 1998; 113: 1329-1334
• 18 Pletz MW, McGee L, Burkhardt O et al. Ciprofloxacin treatment failure in a patient with resistant Streptococcus pneumoniae infection following prior ciprofloxacin therapy. Eur J Clin Microbiol Infect Dis 2005; 24: 58-60
• 19 Höffken G, Lorenz J, Kern W et al. Epidemiology, diagnosis, antimicrobial therapy and management of community-acquired pneumonia and lower respiratory tract infections in adults. Guidelines of the Paul-Ehrlich-Society for Chemotherapy, the German Respiratory Society, the German Society for Infectiology and the Competence Network CAPNETZ Germany. Pneumologie 2009; 63: e1-e68
• 20 Rademacher J, Welte T. Bronchiectasis – diagnosis and treatment. Dtsch Arztebl, Int 2011; 108: 809-815
• 21 Scheinberg P, Shore E. A pilot study of the safety and efficacy of tobramycin solution for inhalation in patients with severe bronchiectasis. Chest 2005; 127: 1420-1426
• 22 Steinfort DP, Steinfort C. Effect of long-term nebulised colistin of lung function and quality of life in patients with chronic bronchial sepsis. Intern Med J 2007; 37: 495-498
• 23 Dhar R, Anwar GA, Bourke SC et al. Efficacy of nebulised colomycin in patients with non-cystic fibrosis bronchiectasis colonised with Pseudomonas aeruginosa. Thorax 2010; 65: 553
• 24 McCoy KS, Quittner AL, Oermann CM et al. Inhaled aztreonam lysine for chronic airway Pseudomonas aeruginosa in cystic fibrosis. Am J Respir Crit Care 2008; 178: 921-928
• 25 Wilson R, Welte T, Polverino E et al. Ciprofloxacin DPI in non-cystic fibrosis bronchiectasis: a phase II randomised study. Eur Respir J 11.10.2012; Epub
• 26 Murray MP, Govan JR, Doherty CJ et al. A randomized controlled trial of nebulized gentamicin in non-cystic fibrosis bronchiectasis. Am J Respir Crit Care Med 2011; 183: 491-499
• 27 Lasserson T, Holt K, Greenstone M. Oral steroids for bronchiectasis (stable and acute exacerbations). Cochrane Database Syst Rev 2001; CD002162. Review
• 28 Tsang KW, Tan KC, Ho PL et al. Inhaled fluticasone in bronchiectasis: a 12 month study. Thorax 2005; 60: 239-243
• 29 Shinkai M, Henke MO, Rubin BK. Macrolide antibiotics as immunomodulatory medications: proposed mechanisms of action. Pharmacol Ther 2008; 117: 393-405
• 30 Anwar GA, Bourke SC, Afolabi G et al. Effects of long-term low-dose azithromycin in patients with non-CF bronchiectasis. Respir Med 2008; 102: 1494-1496
• 31 Wong C, Jayaram L, Karalus N et al. Azithromycin for prevention of exacerbations in non-cystic fibrosis bronchiectasis (EMBRACE): a randomised, double-blind, placebo-controlled trial. Lancet 2012; 380: 660-667
• 32 Bagheri R, Haghi SZ, Fattahi Masoum SH et al. Surgical Management of Bronchiectasis: Analysis of 277 Patients. Thorac Cardiov Surg 2009; 58: 291-294
• 33 Agarwal R. Allergic bronchopulmonary aspergillosis. Chest 2009; 135: 805-826
• 34 Stevens DA, Moss RB, Kurup VP et al. Participants in the Cystic Fibrosis Foundation Consensus Conference. Allergic bronchopulmonary aspergillosis in cystic fibrosis--state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003; 37: 225-264
• 35 Mitchell TA, Hamilos DL, Lynch DA et al. Distribution and severity of bronchiectasis in allergic bronchopulmonary aspergillosis (ABPA). J Asthma 2000; 37: 65-72
• 36 Neeld DA, Goodman LR, Gurney JW et al. Computerized tomography in the evaluation of allergic bronchopulmonary aspergillosis. Am Rev Respir Dis 1990; 142: 1200-1205
• 37 Judson MA, Stevens DA. The treatment of pulmonary aspergilloma. Curr Opin Investig Drugs 2001; 2: 1375-1377 Review
• 38 Imbeault B, Cormier Y. Usefulness of inhaled high-dose corticosteroids in allergic bronchopulmonary aspergillosis. Chest 1993; 103: 1614-1617
• 39 Stevens DA, Schwartz HJ, Lee JY et al. A randomized trial of itraconazole in allergic bronchopulmonary aspergillosis. N Engl J Med 2000; 342: 756-762
• 40 Greenberger PA. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002; 110: 685-692